ATLANTA, GA--(Marketwire - May 22, 2008) - AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that The Lancet, a peer-reviewed medical journal, will publish an article entitled, "Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomized, double-blind, placebo-controlled trial," in this week's May 24, 2008 issue. The article describes the results from AtheroGenics' 6,144-patient ARISE outcome trial of its novel diabetes drug candidate, AGI-1067.
